NS 065

Drug Profile

NS 065

Alternative Names: DMD therapeutics - NCNP/Nippon Shinyaku; Exon 53 skipping antisense oligonucleotide - Nippon Shinyaku/National Center of Neurology and Psychiatry; Exon 53 skipping DMD therapeutic - Nippon Shinyaku/National Center of Neurology and Psychiatry; NCNP-01; NS-065/NCNP-01; NS065

Latest Information Update: 20 May 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator National Center of Neurology and Psychiatry; Nippon Shinyaku
  • Class Antisense oligonucleotides
  • Mechanism of Action Dystrophin expression stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Duchenne muscular dystrophy
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Duchenne muscular dystrophy

Most Recent Events

  • 29 May 2017 NS Pharma plans a phase II trial for Duchenne muscular dystrophy(In children, Treatment-experienced) in Canada and USA (NCT03167255)
  • 01 Feb 2017 NS 065 receives rare paediatric disease designation for Duchenne muscular dystrophy in USA
  • 16 Jan 2017 NS 065 receives Orphan Drug status for Duchenne muscular dystrophy in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top